The IFPMA 2014 Interview Series
The IFPMA Interview Series is a video library of interviews with people from different walks of life talking about topics that are in a way or another related to the industry. The series are about understanding the issues concerning the various IFPMA portfolio-holders and stakeholders; how they perceive those issues as and how they relay the information about these. The IFPMA draws on a wide array of communication strategies and resources to produce a video interview that is easily accessible, well-illustrated with a wealth of information relevant to our different audiences. It is all about asking the intelligent questions our audience would be asking to dig deeper with IFPMA staff and stakeholders and understand better what’s at stake for the different portfolio holders operating in the industry environment and at IFPMA.
It is a unique interview show prepared in advance that starts with thorough research and ends with a rich exchange that can be an eye opener to the industry world. It’s not meant to be a tool for corporate posturing. It’s about intelligent interview based on challenging questions. We take the time to dig deeper with our guests. To offer them space where wordsmithing is not our first worry. The format we chose is short, does not exceed 4 minutes, up to the point and above all people centred.
We hope you enjoy it and if you have any questions or queries regarding this tool, please send it to Ms Sadia Kaenzig : S.Kaenzig(at)ifpma.org
Faced with the current sudden outbreak of Ebola, the World Health Organization (WHO) consulted experts and researchers engaged in Ebola therapies and vaccines research and development (R&D) in 4-5 September 2014. They decided to expedite the development of two of the most advanced vaccines identified so far, one which GlaxoSmithKline (GSK) is co-developing with the Vaccine Research Center of the US National Institutes of Health, and the other being developed by Crucell, one of the Janssen Pharmaceutical Companies of Johnson and Johnson, supported by the US National Institutes of Health. Here is the take of Dr Olga Popova, Johnson & Johnson’s Crucell.
· There are vital components of this ecosystem of innovation that DR Lechleiter, IFPMA President, develops in this interview. The first, is an environment that favors innovation through investment in R&D, the right people in the right place, bringing their ideas to target specific diseases, it requires incentives and intellectual property protection, regulatory system that is timely, predictable, consistent, transparent, and scientifically rigorous to ensure safety, efficacy and quality of the products delivered, and above all it must bring value for patients.